Anti Cancer Fund Ongoing Clinical Trial Funding

The Anti Cancer Fund supports patient-centred clinical research that meets six Selection Criteria and targets one of its high-priority cancer areas. Co-funding is welcome, applications are accepted from any country and any trial phase, and the Fund periodically issues Requests for Applications with a specific scope. Companies (e.g., small biotech, spin-offs, start-ups) are not eligible.

Eligibility Criteria:

• Focus on one of the Fund’s high-priority cancer types:

  • Paediatric solid tumours (including brain tumours and sarcomas).

  • Gynaecological cancers (excluding breast cancer).

  • Adult brain tumours and brain metastases.

  • Hepatobiliary and pancreatic cancers.

• Meet all six Selection Criteria:

  1. Patient-centred (patient engagement; letter from a relevant advocacy group at Full Application; include PROs for efficacy trials).

  2. High scientific value (sound rationale; address any contradictory data).

  3. No commercial interest (off-patent/non-patentable or on-patent where sponsor will not fully fund; document lack of company interest; on-patent drugs donated).

  4. Improving survival or cure rate (ultimate goal).

  5. Limited risk of trial execution failure (experienced investigator-led team; interventions readily available)

  6. Low competition (limited competing trials/interventions; feasible recruitment)

Funding Details:

• Financial support for eligible investigator-initiated clinical trials; co-funding accepted.

• Open to any phase and any country, provided Selection Criteria and priority areas are met.

• Feedback provided even if not funded; may share other funding opportunities.

Deadline:

• Ongoing (spontaneous applications accepted year-round).

• Periodic Requests for Applications may have specific timelines.

Where To Go For Further Information:

• Anti Cancer Fund grants page.